EDIT - Editas Medicine, Inc.
IEX Last Trade
1.23
-0.020 -1.626%
Share volume: 45,359
Last Updated: Thu 26 Dec 2024 08:30:01 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$1.25
-0.02
-1.60%
Fundamental analysis
12%
Profitability
0%
Dept financing
8%
Liquidity
75%
Performance
10%
Performance
5 Days
-3.20%
1 Month
-45.25%
3 Months
-65.33%
6 Months
-74.84%
1 Year
-88.65%
2 Year
-85.51%
Key data
Stock price
$1.23
DAY RANGE
$1.17 - $1.25
52 WEEK RANGE
$1.26 - $11.58
52 WEEK CHANGE
-$88.31
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Gilmore O’Neill
Region: US
Website: editasmedicine.com
Employees: 230
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: editasmedicine.com
Employees: 230
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Editas Medicine, Inc. focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.
Recent news